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	This article was prepared as a result of a symposium dealing with the clinical problem of “nausea and vomiting of pregnancy”. During the symposium many topics were discussed including the mechanism of nausea and vomiting associated with pregnancy and the old and the new innovative treatments that are and have been utilized to manage this clinical problem. The perspective on this subject ranges from the concept that “normal” (what ever that is) nausea is a sign of a healthy pregnancy. This presentation will deal with medical, social and legal implications of treating nausea and vomiting of pregnancy. The problem occurs when the symptoms become exaggerated and result in debilitation, dehydration and hospitalization. It is common knowledge that once the symptoms progress beyond a certain stage, the treatment becomes more difficult. So the treatment of nausea and vomiting of pregnancy in its early stages has the implication that it will prevent the more serious complications, including hospitalization. Therapeutic modalities discussed in this conference that have been utilized or are being tested are primarily symptomatic treatments (antihistamines, Bendectin, phenothiazines, hypnosis, accupressure, relaxation behavioral modification, audiogenic feedback training, newer medications, diet and nutritional support). Some of them, such as Bendectin have been studied extensively with regard to their reproductive effects. Bendectin is probably the most studied medication with regard to its reproductive effects and the studies clearly (Brent 1983, 1985a,b, Brent et al. 1989, 1995a, 1997) demonstrate that Bendectin has no measurable reproductive risks to the mother of the fetus. But others therapies have been minimally studied or have not been studied at all.
	My role in this conference is to discuss the ethical and legal issues that pertain to this topic and how they have been amplified by the Bendectin era. There is no question that there were non-meritorious congenital malformation lawsuits that were filed and went to trial and that junk science was presented at trials during congenital malformation lawsuits (Brent 1967, 1977, 1982, 1987, 1992a, 1995c). But the Bendectin era focused our attention on the area on non-meritorious litigation (Brent 1995b,c) and junk science.
	While some aspects of this discussion may appear to be critical of the legal profession, it is important to place this criticism into perspective. Physicians, as a group, tend to be hypercritical of the legal profession because of the escalation of malpractice litigation and malpractice insurance premiums. Recommendations from the medical community to modify the law in order to reduce the frequency of non –meritorious litigation and the size of the awards have been minimally successful, primarily because lawyers dominate the legislatures. Furthermore, many of these attempts by physicians to change the law are naïve. My suggestions in the past have directed the medical community to focus their attention on junk scientists and their junk science, since they are problems that emanate from the medical community, over which physicians should have some authority (Brent 1977.1982, 1987, 1992a, 1995c
	More importantly, we should respect and admire the importance and accomplishments of the legal profession, because it is the foundation of any thriving democracy. Without the law, we could never have rid ourselves of a sitting president or protected all of the rights bestowed on individuals in our constitution. Because a very small percentage of attorneys exploit the power of the law to their own advantage, does not mean that the legal system has to be replaced or eliminated. It is to everyone’s advantage to have a functioning legal system with its benefits and risks. Remember that many non-meritorious lawsuits could not proceed, if it were not for the testimony of a junk scientist who appears before a judge and testifies that the case has merit. Many of these junk scientists are obstetricians and pediatricians as well as other members of the clinical and scientific community (Brent 1982. 1995a. 1997).
	The problem of managing the clinical care of pregnant women with nausea and vomiting is epitomized by the Bendectin era, the period from 1960 to the year 2000. A review of this history delineates the problems we face as well as the potential solutions.
Historical Perspective
1960s 
Lawsuits alleging that various phenothiazines and antihistamines caused birth defects: There was an increase in the number of lawsuits involving malformed children and their families as plaintiffs (Brent 1967). Many of the lawsuits involved an anti-nausea medication, such as meclizine. The first meclizine lawsuit, with which I was acquainted, involved a child with EEC syndrome (ectrodactyly, ectodermal dysplasia and cleft palate), which is a genetic disease. Scientists from a prestigious University and the NIH testified that meclizine caused this child’s defect, which, of course, was present at the time of conception, before there was any exposure to the medication. 
Bendectin containing doxylamine succinate, dicyclomine and pyridoxine listed as appropriate for the treatment of NVP: The FDA approved labeling for Bendectin as the only drug formerly recommended for the treatment of nausea and vomiting in pregnant women
1970s 
National Academy of Sciences (NAS) listed Bendectin as possibly effective: A committee of the National Academy of Sciences evaluated a long list of medications with regard to their effectiveness. The manufacturer of Bendectin was of the opinion that the therapeutic benefits were greater than that expressed by the NAS and commissioned further studies of Bendectin’s effectiveness in a double blind study.
A Peer review group of 15 toxicologists, epidemiologists, obstetricians and teratologists reviewed the NAS opinion and suggested that a double-blind study be performed utilizing various combinations of the constituents in Benedectin. The results of these studies indicated that dicyclomine did not contribute to Bendectin’s effectiveness. A new Bendectin compound was reformulated without dicyclomine.

1980s and 1990s
FDA Maternal Health Drug Committee deliberations: In the early 1980’s the FDA Maternal Health Drug Committee discussed Bendectin at several of their meetings and actually held open hearings on the merits of the allegation that Bendectin caused congenital malforamtions. Before the committee could formulate a definitive conclusion, the deliberative process was terminated by political intervention by a member of congress.
Mekdeci lawsuit initiated, followed by the Ohio class action lawsuit and numerous individual lawsuits: The plaintiff in the Mekdeci lawsuit had Poland Syndrome. The limb malformation was unilateral. Poland Syndrome is thought to be due to vascular disruption. In some cases the disease is familial. The only epidemiological data available in the early 1980s did not support the allegation that Bendectin could cause Poland Syndrome. In the first trial the jury determined that Bendectin did not cause the malformations, but they awarded $20,000.00 to the family. The jury’s explanation was that they wanted to compensate the family, but the judge reversed the decision. In the second trial, the jury rendered a defense verdict. 
The class-action lawsuit in Ohio was supervised by Judge Hoffman who negotiated a settlement of $170,000,000.00. There were more than a thousand plaintiffs in this class-action lawsuit. The plaintiff attorneys rejected the negotiation and the cases went to trial. The trial resulted in a defense verdict.
Insurance premiums exceed gross sales for Bendectin and the manufacturer stopped marketing Bendectin. Unavailability of Bendectin resulted in an increase in admissions to hospitals in USA for severe NVP. With the withdrawal of Bendectin from the market in the United States, the exposure to the population of pregnant women dropped dramatically. In the 1970s the percentage of pregnant women taking Bendectn was as high as 30% to 35%. The frequency of limb reduction defects and congenital heart disease remained the same during the 1980s; a period when pregnant women had practically no exposure to Bendectin. This type of secular trend divergence in the frequency of exposure and the frequency of malformations allegedly caused by Bendectin, is not supportive of the allegation that Bendectin is a human teratogen. 
Peer review group convened by the Canadian government and the preparation (Diclectin) is continued on the market: A Member of Parliament was concerned about all the notoriety that Bendectin was receiving in the newspapers in the United States. He requested that the Canadian equivalent of the FDA review the data pertaining to the teratogenicity of Bendectin. The equivalent drug in Canada is labeled Diclectin. I was a member of the review panel along with other consultants and members of the drug approval branch of the Canadian government. The panel published their findings and Diclectin was kept on the market (Brent et al. 1987). 
Relevant publications and lawsuits
Numerous negative cohort, case control human studies, animal studies, in vitro studies, commentaries and meta-analyses were published. There were hundreds of articles and letters published about Bendectin. It is of interest that not a single review article was written by any of the plaintiff experts about Bendectin. The most recent complete review of the subject was published in 1995 and reprinted with some modifications in 1997 (Brent 1995a, 1997).
Important Bendectin lawsuits
1.	Mekdeci: Poland syndrome
2.	Class Action Lawsuit in Ohio
3.	Hagaman case (1988): Split-hand syndrome
4. 	Farrell: An example of legal ethics
5. 	Daubert: Supreme Court decision
6.	Depyper (1995): Friend of the court opinions
7.	Blum (2000) Club feet secondary to mild Ehlers-Danlos syndrome

A number of the important lawsuits have already been discussed, but a number of others are equally important. The Hagaman case involved a plaintiff with a typical split-hand, split-foot syndrome that is due to a dominant gene, either inherited or mutated during oogenesis or spermatogenesis. Alleging that Bendectin caused this malformation is scientifically nonsensical. 
The Daubert decision allows a judge to prevent the testimony of an expert if that witness does not utilize acceptable scientific methodology. Many experts for the plaintiff in the Bendectin litigation had their testimony rejected by the courts. This was an important and monumental decision. 
In the Depyper trial, the judge requested experts to testify as friends-of-the-court. Something that I suggested many years ago (Brent 1967). 
The Blum case involved a child that was born with club feet and had to have surgery more than once, because the first surgery was unsuccessful. A clinical geneticist examined the family and concluded that the family had mild symptoms of Ehlers-Danlos syndrome which accounted for the failed surgery. The first and second trial resulted in plaintiff verdicts, but was reversed by appeals to superior courts. This case is an example of the length of time that a family can be involved in litigation
Benefits and Risks of Introducing Medication and Treatment for NVP.
Benefits of effective treatment: It is obvious that there are clinical, psychological and social benefits that will result from any effective therapy that reduces or eliminates the symptoms of nausea and vomiting in pregnant women. This topic has been addressed by other contributors to this symposium and includes the following benefits:
Symptomatic improvement and comfort.
Optimal nutrition for mother and fetus
Decreased risk of some pregnancy complications
Psychological benefits
Decrease absenteeism for working mothers
Decrease difficulty in managing the home and family

Medical risks of therapeutic intervention: The medical risks of any therapy have two implications. The first is that the therapy may be unacceptable to the patient or represent a medical risk that is unacceptable to the physician and the patient. In other circumstances the risk of a new therapy theoretically could be more significant than the benefit of relieving the nausea and vomiting. But some of these risks, if they occur, could lead to litigation. The most serious medicolegal risk is the occurrence of embryonic and fetal malformations (Brent 1977). The risks include:
Side effects of the therapy in pregnant woman.
Deleterious effects of the therapy on the embryo or fetus.
Idiosyncratic reactions.
Ineffectiveness of the therapy.
Risk of the patient selecting herbal or home remedies.

Legal risks of therapeutic intervention: 
Alleging that the therapy was not effective.
Alleging that side effects of therapy are the result of negligence by the physician or manufacturer.
Alleging that maternal reproductive problems are the result of negligence by the physician or manufacturer.
Alleging that birth defects, abortion or fetal pathology are the result of negligence by the physician or manufacturer.

Since many of the therapies that have been discussed at this symposium are relatively new, there is minimal data on which to base an evaluation of the risk of reproductive effects. Unfortunately, attorneys can be creative in generating hypotheses and obtaining witnesses who are willing to support hypotheses that implicate the therapy as having teratogenic potential. Even when therapies such as accupressure, hypnosis, psychotherapy or psychological condtioning appear to be very unlikely to harm the fetus, that does not prevent a lawsuit from being initiated, if a severely malformed fetus resulted from that pregnancy. Therefore, the best protection for the patient, the physician, the manufacturer of a drug or the developer of a therapeutic technique is to have abundant data that indicates that the therapy has no measurable harmful effects on the developing embryo or fetus, as well as pregnant women. Unfortunately, there is only one therapy that fits these criteria and that is Bendectin. There are over 13,000 patients in 12 cohort studies and numerous case control studies that indicate that Bendectin does not represent a measurable risk to the developing mother or fetus. Furthermore the animal studies and in-vitro studies support this conclusion (Brent 1995a, 1997). No other treatment of nausea and vomiting during pregnancy has the demonstrated low risk record of Bendectin.
Clinical and Research Recommendations
Research on the physiology and mechanism of NVP; its benefits and risks. We should design therapy based on the basic science aspects of NVP: Most of the therapies and research discussed at this symposium can be labeled as symptomatic treatment. The answer to any clinical problem is best derived from mechanistic research. In other words: What pregnancy metabolic product is interacting with what brain receptor that induces nausea and vomiting in pregnant women? It would seem most logical that a major research effort should be directed toward brain receptors that are involved in these physiological effects. Furthermore, it would be imperative to study the array of molecules; both natural and manufactured that can interact with these receptors. We have models of angiotensin II receptor blockers and endothelin receptor blockers that are used for the treatment of hypertension. A similar approach could be utilized to study the mechanism of nausea and vomiting during pregnancy and to develop an effective and safe therapy.
Standardization of the use of anti-nausea medication with regard to the most appropriate dose, type of phenothiazine, antihistamine or combination of agents: It is very likely that many of the phenothiazines and antihistamines would be effective therapies for nausea and vomiting and represent very low risks to the embryo. The problem is that there are so many of these products that there is not enough epidemiological data collected in pregnant women to document the fact that they represent no measurable risk to the developing embryo or fetus. The method utilized to perform such an evaluation is listed below.
Evaluating the allegation of teratogenicity (Brent 1978, 1986) (Table 1)
1.  Consistency of epidemiological studies
2.  Secular trend analysis
3.  Animal reproductive studies
4.  Dose response relationships and pharmacokinetic studies, comparing human and animal metabolism.
5.  Biological plausibility
        a. Mechanisms
        b. Receptor studies
        c. Nature of the malformations
        d. Teratology principles

But we already  have data in all five categories for Bendectin, because it is the most widely studied medication with regards to its reproductive effects. None of the other antihistamines or phenothiazines have enough data to perform the kind of complete evaluation that can be performed for Bendectin.
Reintroduction of doxylamine succinate-pyridoxine combination as the only medication to be used in NVP: At this time, it would appear that the most conservative approach to solve the problem of providing effective therapy for nausea and vomiting of pregnancy is the reintroduction of Bendectin for use in pregnant women. The first reason for making this recommendation is that the therapy is effective. Secondly, because of the massive amount of data on its lack of reproductive risks, it would provide a bulwark against any litigation that might be initiated by families of malformed children from Bendectin-treated pregnancies.
Of course that should not stop investigation into the mechanism of nausea and vomiting in pregnancy and the development of more specific therapies based on receptor physiology and modern drug development techniques. 
Anticipating the Legal Risks and Implications
	Be aware of the fact that if 30% of pregnancies are treated with a medication or non-medication-therapy, then 30% of malformed children will have been exposed to that therapy. That is why Bendectin and sex steroid lawsuits were so prevalent (Brent 1995, 1997, Wilson and Brent 1981, Corfman 1988, Brent 1989, FDA 1999a, Table 1)
What are the Circumstances that Stimulate Negligence Lawsuits?
1.	Birth Defects: a plaintiff that generates sympathy and where the defense expert is frequently unable to be certain of the etiology of the child’s birth defect and the plaintiff expert is certain (Brent 1967, 1977, 1982).
2.	A high proportion of exposures in the population at risk.
3.	An area where junk scientists are readily available.
4. 	Jurisdictions that are known for plaintiff verdicts.
5. 	An area where a significant number of law-firms are focusing their attention.
6.	A new area (drug) for which little data is available and therefore hypotheses without data can be generated.

Recommendations Pertaining to the Legal Risks 
1. Introduce legislation similar to the Vaccine Injury Compensation Act.  I believe that if we followed the model of the Vaccine Injury Compensation Act, it would be a serious error. The question of vaccine injury to immunized children was a very controversial issue in the medical community. While the risks were very small, the number of lawsuits that were initiated was very large. The data pertaining to Bendectin is much more decisive and from the scientific vantage point, not controversial, with regard to its reproductive effects. Therefore, there is better approach to solve the problem of potential litigation than to pursue legislation similar to the Vaccine Injury Compensation Act.
2. Reintroduce Bendectin (doxylamine succinate-pyridoxine). Until we understand the mechanism and specific therapy for nausea and vomiting, it would appear that the reintroduction of Bendectin is the logical intermediate course to follow. Accompany the introduction of Bendectin with an educational campaign with regard to the lack of reproductive risks for this medication. 
In 1999 the FDA published a statement in the Federal Register which summarizes the organizations opinion on the lack of teratogenicity of Bendectin (FDA 1999b)
Summary: The Food and Drug Administration has determined that the drug product Bendectin, a tablet composed of pyridoxine hydrochloride, 10 milligram (mg), and doxylamine succinate, 10 mg, for the prevention of nausea during pregnancy was not withdrawn from sale for reasons of safety or effectiveness. This determination will permit FDA to approve abbreviated new drug applications (ANDA’s) for the combination product pyridoxine hydrochloride, 10 mg, and doxylamine succinate, 10 mg, tablets.
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Immunologically & clinically diagnosed abortions per million conceptions.	350,000
	
Clinically recognized spontaneous abortions per million clinically recognized pregnancies	150,000
	
Genetic Diseases per million  births	110,000
	Multifactorial or polygenic genetic environmental interactions)	90,000
	Dominantly inherited disease	10,000










Stillbirths (>20 wk._)          	  4,000-20,900
	
Infertility	7% of couples
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